DiaGen AI Inc., founded in 2021 to enhance AI-driven drug discovery solutions, has appointed Ali Urman as the leader of its advisory board. This move aims to strengthen the company’s focus on advancing its innovative pipeline in protein-related discoveries. Additionally, DiaGen plans to participate in upcoming conferences, further promoting its advancements in artificial intelligence within the biotechnology sector. The announcement highlights the company’s commitment to leveraging AI for significant breakthroughs in drug discovery.